| 62.92 0.81 (1.3%) | 01-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 76.37 |
1-year : | 89.2 |
| Resists | First : | 65.38 |
Second : | 76.37 |
| Pivot price | 62.73 |
|||
| Supports | First : | 62.3 |
Second : | 60.4 |
| MAs | MA(5) : | 62.08 |
MA(20) : | 62.8 |
| MA(100) : | 57.45 |
MA(250) : | 49.24 |
|
| MACD | MACD : | 0.3  |
Signal : | 0.6 |
| %K %D | K(14,3) : | 46.8 |
D(3) : | 35.6 |
| RSI | RSI(14): 52.7 |
|||
| 52-week | High : | 65.57 | Low : | 32.47 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ LIVN ] has closed below upper band by 46.5%. Bollinger Bands are 20.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 63.05 - 63.5 | 63.5 - 63.84 |
| Low: | 59.97 - 60.43 | 60.43 - 60.8 |
| Close: | 62.3 - 63.03 | 63.03 - 63.6 |
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Tue, 20 Jan 2026
LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results - marketscreener.com
Tue, 20 Jan 2026
LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results - Business Wire
Thu, 15 Jan 2026
LivaNova Announces Chief Legal Officer Resignation and Succession - The Globe and Mail
Tue, 13 Jan 2026
LivaNova PLC (LIVN) Stock Analysis: Exploring a 17% Potential Upside in the Medical Device Sector - DirectorsTalk Interviews
Sat, 10 Jan 2026
LivaNova (LIVN) Is Up 6.2% After Fresh Analyst Optimism on Advanced Therapies Portfolio - What's Changed - Sahm
Fri, 09 Jan 2026
Barclays Raises Price Target for LivaNova (LIVN) Amidst Consistent Ratings | LIVN Stock News - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 55 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 105.2 (%) |
| Shares Short | 2,030 (K) |
| Shares Short P.Month | 2,290 (K) |
| EPS | -3.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 21.19 |
| Profit Margin | -16.2 % |
| Operating Margin | 16.5 % |
| Return on Assets (ttm) | 5.2 % |
| Return on Equity (ttm) | -17.7 % |
| Qtrly Rev. Growth | 12.5 % |
| Gross Profit (p.s.) | 17.14 |
| Sales Per Share | 24.72 |
| EBITDA (p.s.) | 4.72 |
| Qtrly Earnings Growth | -18.3 % |
| Operating Cash Flow | 251 (M) |
| Levered Free Cash Flow | 890 (M) |
| PE Ratio | -15.81 |
| PEG Ratio | 0 |
| Price to Book value | 2.96 |
| Price to Sales | 2.54 |
| Price to Cash Flow | 13.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|